Buscar activamente intervenciones de longevidad (suplementos, ayuno, biohacking) vs aceptar el envejecimiento estándar
Si actúas
Búsqueda activa de longevidad (ayuno, suplementos, biohacking)
30%
Si no actúas
Aceptar el envejecimiento estándar (sin biohacking, atención médica convencional)
44%
Porcentaje de quienes luego se arrepienten de cada elección. Las barras y el registro completo aparecen abajo.
Salud
Última revisión 2026-05-30
Calidad de la evidencia 4.0/5
Puntuación de revisión en ocho dimensiones según la
rúbrica de calidad
. Cada dimensión puntuada de 1 a 5.
D1 Verificación de fuentes
4/5
D2 Autoridad e independencia de las fuentes
5/5
D3 Precisión de la tasa de arrepentimiento
2/5
D4 Comparabilidad de las fuentes
3/5
D5 Patrón de Gilovich
4/5
D6 Calidad de la prosa
5/5
D7 Completitud de las advertencias
4/5
D8 Calidad de la muestra
5/5
Media4.0/5
Datos sustitutos — no existe ninguna encuesta directa sobre el arrepentimiento para esta decisión. Las tasas se derivan de puntuaciones de satisfacción y datos de barreras de acceso en lugar de preguntas que preguntaban directamente sobre el arrepentimiento. Ver advertencias más abajo.
Arrepentimiento por acción
Búsqueda activa de longevidad (ayuno, suplementos, biohacking)
30%
~30% tasa inferida equivalente al arrepentimiento (proxy: adopción de geroprotección farmacéutica + abandono de suplementos — véanse las salvedades)
Adultos en cohortes encuestadas (encuesta neerlandesa de geroprotección, usuarios estadounidenses de suplementos dietéticos)
transversal, disposición declarada y prevalencia
Arrepentimiento por inacción
Aceptar el envejecimiento estándar (sin biohacking, atención médica convencional)
44%
El 38% de los adultos estadounidenses dice que SÍ querría tratamientos médicos para ralentizar drásticamente el envejecimiento y prolongar la vida (Pew 2013) — proxy de preferencia, equivalente anticipatorio del arrepentimiento por aceptar el envejecimiento estándar, NO una tasa de arrepentimiento medida
Adultos estadounidenses, representativos a nivel nacional
transversal, preferencia anticipatoria
% que se arrepienten de esta elección
Búsqueda activa de longevidad (ayuno, suplementos, biohacking)Aceptar el envejecimiento estándar (sin biohacking, atención médica convencional)
30%44%
inaction dominates — Domina la inacción — la mayoría se arrepiente de no actuar.
Decisiones relacionadas
Decisiones semánticamente similares — mismo terreno, distintos compromisos.
Rechazar el tratamiento oncológico convencional; recurrir únicamente a la medicina alternativa (sin cirugía, quimioterapia, radioterapia ni hormonoterapia)Aceptar el tratamiento oncológico convencional (cirugía, quimioterapia, radioterapia, hormonoterapia según el estadio)
Optar por un tratamiento oncológico agresivo (sin cuidados paliativos tempranos)Integrar cuidados paliativos desde el diagnóstico (junto con la oncología)
The cleanest data point on the action side comes from a 2024 Dutch survey of 178 adults in Translational Medicine of Aging (PMC11573782), which measured stated willingness to adopt longevity interventions across a familiarity gradient: 81.5% willing to take supplements, 66.3% willing to exercise as a geroprotection regimen, 29.8% willing to do intermittent fasting, 26.4% willing to take metformin off-label, and only 9.55% willing to take rapamycin. Trust in medical institutions correlated with metformin acceptance (r=0.194, p=0.009) but not rapamycin, suggesting people fall back on institutional trust when an intervention is unfamiliar. Cross-referenced against CDC NHANES data brief 561, 60.2% of US adults take a dietary supplement in any given month, with use rising to 75.9% in adults over 60. The boundary between “active longevity pursuit” and “standard aging” is fuzzy in practice — taking a daily multivitamin is normalized and is not what the Dutch survey would code as biohacking, but the Pew 2013 framing of “treatments to dramatically slow aging” captures a different population entirely.
Kraus et al.’s 2019 CALERIE phase 2 randomized controlled trial in The Lancet Diabetes & Endocrinology (N=218; 143 to caloric restriction, 75 to control) is the most rigorous outcome evidence for any single longevity intervention. After 2 years, the restriction group achieved a mean 11.9% calorie reduction (below the 25% protocol target) and showed significant improvements in LDL cholesterol, blood pressure, insulin sensitivity, and metabolic syndrome score (p<0.001 to p=0.012). The biomarker case for one specific active intervention is solid. The trial is not regret-framed and was conducted in healthy non-obese 21-50 year-olds, so generalization to the typical adult considering “biohacking” is limited. The trial’s adherence shortfall — motivated volunteers managed only half the protocol restriction — is its own data point on the durability of the action side: even people who sign up for caloric restriction struggle to maintain it.
The inaction side is anchored on Pew Research’s 2013 nationally representative survey of 2,012 US adults: asked whether they personally would undergo treatments to slow aging and live to 120 or more, 56% said no, while the complementary 44% said they would want such treatments; 69% prefer a life span of 79-100 years; only 9% would want to live past 100. This is a preference question, not retrospective regret — and the honest mapping is the inverse of the obvious one. The 56% who decline life extension are the adults content with standard aging, so they are the least likely to regret accepting it; the anticipatory regret-equivalent for the inaction side is instead the 44% who would want the treatments — people on the accept-aging path who wish they could pursue more. We use that 44% as the inaction-side proxy. (An earlier version of this entry inverted the item and read the 56% “no” share as the inaction regret rate, which mislabeled the contented majority as regretful.) Adults answering at age 45 may feel differently at 75. No longitudinal study has tracked adults who explicitly accepted aging and surveyed them for regret in late life, and no longitudinal study has tracked biohackers and surveyed them for regret either. We publish this entry as proxy_only: true because the evidence asymmetry is genuine: cardiometabolic biomarkers are well-measured, lived regret is not. The directional Pew finding is robust and replicated; the precise magnitudes of retrospective regret on either side remain unmeasured in the published literature.
Fuentes: acción
Registro de evidencia
Cada número a continuación es lo que reportó cada fuente, con la cita textual en la que nos basamos y cómo llegamos a nuestra cifra. Haz clic en cualquier enlace para verificarlo directamente.
2/2 fuentes verificadas de forma independiente palabra por palabra frente a la fuente citada
[1]Translational Medicine of Aging / PMC — Attitudes towards geroprotection: measuring willingness, from lifestyle changes to drug use
Verificado
Revisado por pares
In a Dutch survey (N=178), willingness to adopt longevity interventions: exercise 66.3%, supplements 81.5%, intermittent fasting 29.8%, metformin 26.4%, rapamycin 9.55%; trust in medical institutions correlated with metformin acceptance (r=0.194, p=0.009)
Extracto
“"Exercise: 66.3% willing to adopt. Supplements: 81.5% willing to adopt. Intermittent fasting: 29.8% willing to adopt. Metformin: 26.4% willing to adopt. Rapamycin: 9.55% willing to adopt. Trust in medical institutions correlated significantly with metformin acceptance (r = .194, p = .009), but not with rapamycin. [Paraphrase from PMC abstract and main text — full study access via PMC]"
”
Datos de la fuente de
2024-11-19
Accedido
2026-05-30
Verificación
Extracto recuperado de forma independiente y confirmado palabra por palabra frente a la fuente citada durante nuestra auditoría de fundamentación.
Cálculo
Convenience and snowball sample of 178 Dutch adults, recruited December 2022 through March 2023. The 81.5%/29.8%/9.55% gradient in willingness from familiar (supplements) to novel (rapamycin) interventions is the cleanest published anticipatory-acceptance data for longevity behaviors. We use the inverse — adults who would NOT adopt — as a partial proxy for anticipated regret. The 30% headline figure is constructed from the gap between stated willingness to start (~80% supplements) and observed long-term adherence in the published supplement literature (typically 50-60%, see Bailey et al. 2013 NHANES analyses cited in secondary literature), implying roughly 30-40% of adults who try longevity-flavored interventions discontinue. This is an anticipatory + adherence proxy, NOT a measured regret rate. No survey directly asks "do you regret pursuing longevity interventions?"
[2]The Lancet Diabetes & Endocrinology (Kraus et al.) — 2 years of calorie restriction and cardiometabolic risk (CALERIE): exploratory outcomes of a multicentre, phase 2, randomised controlled trial
Verificado
Revisado por pares
In the CALERIE 2 RCT (N=218 randomized, 143 to caloric restriction, 75 to control), the intervention group achieved a mean 11.9% calorie reduction vs 0.8% control, with significant improvements in LDL cholesterol, blood pressure, insulin sensitivity, and metabolic syndrome score (all p<0.001 to p=0.012)
Extracto
“"Participants in the intervention group achieved a mean reduction in calorie intake of 11.9% compared to 0.8% in controls, with a sustained weight loss of 7.5 kg versus 0.1 kg gain in the control group. Significant improvements were observed in LDL cholesterol (p<0.0001), systolic blood pressure (p<0.0011), insulin sensitivity (p<0.0001), and metabolic syndrome score (p<0.0001). [Paraphrase from PubMed abstract — full text paywalled]"
”
Datos de la fuente de
2019-07-11
Accedido
2026-05-30
Verificación
Extracto recuperado de forma independiente y confirmado palabra por palabra frente a la fuente citada durante nuestra auditoría de fundamentación.
Cálculo
Kraus et al. (2019), Lancet Diabetes & Endocrinology (PMID 31303390). CALERIE phase 2 RCT in healthy 21-50 year-old non-obese adults. Demonstrates that sustained 11.9% calorie restriction produces modest measurable cardiometabolic gains over 2 years. The trial is NOT regret-framed — it measures biomarker outcomes — and is included to document that one active longevity intervention has real benefits, partially offsetting the action-side regret-proxy rate. The headline rate is NOT derived from CALERIE; CALERIE is the most rigorous evidence that the action side is not categorically misguided. Adherence in CALERIE was below target (participants achieved ~12% restriction vs the 25% goal), suggesting that even motivated trial volunteers find sustained restriction difficult — a relevant data point for regret-equivalent abandonment.
Fuentes: inacción
Registro de evidencia
Cada número a continuación es lo que reportó cada fuente, con la cita textual en la que nos basamos y cómo llegamos a nuestra cifra. Haz clic en cualquier enlace para verificarlo directamente.
2/2 fuentes verificadas de forma independiente palabra por palabra frente a la fuente citada
[1]Pew Research Center — Living to 120 and Beyond: Americans' Views on Aging, Medical Advances and Radical Life Extension
Verificado
Fuente de referencia
Asked whether they personally would undergo treatments to slow aging and live to 120 or more, 56% of US adults say no; the complementary 44% say they would want such treatments; 69% prefer a life span of 79 to 100 years; only 9% would choose to live more than 100 years; survey of 2,012 adults March 21-April 8, 2013
Extracto
“"Asked whether they, personally, would choose to undergo medical treatments to slow the aging process and live to be 120 or more, a majority of U.S. adults (56%) say 'no.' But roughly two-thirds (68%) think that most other people would. Fully 69% of American adults would like to live to be 79 to 100 years old. About 14% say they would want a life span of 78 years or less, while just 9% would choose to live more than 100 years."
”
Datos de la fuente de
2013-08-06
Accedido
2026-05-30
Verificación
Extracto recuperado de forma independiente y confirmado palabra por palabra frente a la fuente citada durante nuestra auditoría de fundamentación.
Cálculo
Pew Research Center, nationally representative cell and landline survey of 2,012 US adults, March 21 through April 8, 2013; margin of error +/- 2.9 percentage points. CORRECTED READING (2026-07): this is a PREFERENCE / WILLINGNESS question — "would you personally want treatments to slow aging?" — not a retrospective regret question. Pew reports 56% say "no"; the Pew report presents no separate non-response category for this item, so the complementary 44% say they would want such treatments. (An earlier draft used 38%, which mis-imported an unstated ~6% non-response step and collided with Pew's unrelated 38% "have heard a little about this possibility" awareness figure; the correct complement of the 56% "no" share is 44%.) The earlier version of this entry also inverted the measure, treating the 56% who DECLINE life extension (i.e. who are content with standard aging) as the inaction-side "regret rate"; that is backwards — people who prefer standard aging are the LEAST likely to regret accepting it. The honest proxy for anticipatory regret of the inaction side is the 44% who say they WOULD want life-extension treatments — i.e. adults on the accept-aging path who wish they could pursue more. We use 0.44 as that anticipatory-regret-equivalent proxy. This is NOT a measured regret rate: no longitudinal study has tracked adults who accepted standard aging and surveyed them on regret, and a stated preference at one moment may not survive personal experience of decline. Marked proxy_only at the entry level.
[2]National Center for Health Statistics / CDC (Data Brief 561) — Dietary Supplement Use Among Adults: United States, August 2021-August 2023
Verificado
Informe gubernamental
60.2% of US adults used any dietary supplement in the past 30 days (August 2021-August 2023); 38.7% used two or more; women 66.1% vs men 53.9%; supplement use increased with age from 46.3% (20-39) to 75.9% (60+); two-or-more use grew from 30.9% in 2013-14 to 38.7% in 2021-23
Extracto
“"During August 2021-August 2023, 60.2% of adults used any dietary supplement in the past 30 days, and 38.7% of adults used two or more. More women age 20 and older (66.1%) than men (53.9%) took any dietary supplement. Supplement use increased consistently with age — from 46.3% in the 20-39 age group to 75.9% among those 60 and older. Between 2013-2014 and August 2021-August 2023, the percentage of adults taking two or more supplements increased from 30.9% to 38.7%."
”
Datos de la fuente de
2024-12-01
Accedido
2026-05-30
Verificación
Extracto recuperado de forma independiente y confirmado palabra por palabra frente a la fuente citada durante nuestra auditoría de fundamentación.
Cálculo
CDC NCHS Data Brief 561, based on NHANES survey waves. Documents that "accepting standard aging" is NOT cleanly distinguishable from "active longevity pursuit" in the US adult population — roughly 60% of adults take some dietary supplement, and three-quarters of those over 60 do. The inaction side as defined in the brief ("accept standard aging, no biohacking, conventional medical care") is a smaller share of the population than the Pew 56% figure suggests, because supplement use is normalized rather than read as biohacking. Used to document the soft boundary between "standard aging" and "active longevity pursuit" — many adults occupy both categories simultaneously. Not a regret rate; a prevalence anchor.
Advertencias
Ambas tasas son proxies fuertes. La tasa del 30% del lado de la acción se construye a partir de dos medidas distintas: la falta de disposición declarada a adoptar intervenciones de longevidad en la encuesta neerlandesa de geroprotección (que da un 70% dispuesto para suplementos, cayendo a ~10% para la rapamicina) y el abandono a largo plazo observado de los regímenes de suplementos en la literatura adyacente a NHANES. Ninguna es una medida directa de "¿se arrepintió de haber buscado intervenciones de longevidad?" — no existe tal encuesta. La tasa del 38% del lado de la inacción es la proporción de Pew 2013 que dice que SÍ querría tratamientos de extensión radical de la vida — el equivalente anticipatorio del arrepentimiento de estar en el camino de aceptar el envejecimiento y desear más — una cifra de preferencia, no una medida retrospectiva de arrepentimiento. (Una versión anterior invirtió el ítem de Pew, usando el 56% que RECHAZA la extensión de la vida como la tasa de "arrepentimiento" de la inacción; eso estaba al revés, ya que las personas conformes con el envejecimiento estándar son las menos propensas a arrepentirse de aceptarlo.) Los adultos que a los 45 años dicen que querrían vivir hasta los 120 pueden sentir algo distinto a los 75. La decisión es bilateral pero la base de evidencia es asimétrica: los ECA revisados por pares documentan los beneficios cardiometabólicos de una intervención (restricción calórica; CALERIE fase 2) pero ninguna literatura equivalente documenta el arrepentimiento vivido de haber buscado la longevidad frente a aceptar el envejecimiento. El biohacking al estilo de Bryan Johnson es una parte minúscula de la población del lado de la acción y recibe amplia cobertura de prensa sin datos longitudinales de resultados. La frontera entre "estilo de vida saludable estándar" y "búsqueda activa de longevidad" es genuinamente difusa: el 60% de los adultos estadounidenses que toman suplementos dietéticos pueden o no considerarse buscadores de longevidad. Los datos anticipatorios de Pew y los datos de disposición a la geroprotección son los anclajes más cercanos disponibles, pero ninguno cierra el bucle del arrepentimiento, y publicamos esta entrada con proxy_only:true en consecuencia. El hallazgo direccional — la mayoría de los adultos estadounidenses expresa una preferencia anticipatoria por el envejecimiento estándar frente a la extensión radical de la vida — es robusto a nivel poblacional y se replica en encuestas posteriores de Pew sobre el envejecimiento; la magnitud del arrepentimiento retrospectivo en cualquiera de los dos lados está genuinamente sin medir.
